Your browser doesn't support javascript.
loading
Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies.
Tini, Giacomo; Tocci, Giuliano; Battistoni, Allegra; Sarocchi, Matteo; Pietrantoni, Camilla; Russo, Domitilla; Musumeci, Beatrice; Savoia, Carmine; Volpe, Massimo; Spallarossa, Paolo.
Afiliação
  • Tini G; Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy. giacomo.tinimelato@uniroma1.it.
  • Tocci G; IRCCS San Raffaele Pisana, Rome, Italy. giacomo.tinimelato@uniroma1.it.
  • Battistoni A; Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy.
  • Sarocchi M; Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy.
  • Pietrantoni C; Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino-IRCCS Italian Cardiology Network, Genoa, Italy.
  • Russo D; Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy.
  • Musumeci B; Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy.
  • Savoia C; Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy.
  • Volpe M; Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy.
  • Spallarossa P; Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy.
Curr Heart Fail Rep ; 20(1): 56-62, 2023 02.
Article em En | MEDLINE | ID: mdl-36696001
PURPOSE OF THE REVIEW: Arterial hypertension (AH) is the most common cardiovascular (CV) risk factor in the community and in oncologic patients. It also represents the most important CV condition predisposing to anticancer treatment-related cardiotoxicity. This risk is heightened in the presence of cardiac AH-mediated organ damage (HMOD). Influence of AH and HMOD on the development of cardiotoxicity will be reviewed, with a focus on specific scenarios and implications for management of oncologic patients. RECENT FINDINGS: Not adequately controlled AH before or during anticancer treatments and/or development of AH during or after completion of such therapies have detrimental effects on the clinical course of oncologic patients, particularly if HMOD is present. As overlooking CV health can jeopardize the success of anticancer treatments, the goal for clinicians caring for the oncologic patient should include the treatment of AH and HMOD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Insuficiência Cardíaca / Hipertensão Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Curr Heart Fail Rep Assunto da revista: CARDIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Insuficiência Cardíaca / Hipertensão Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Curr Heart Fail Rep Assunto da revista: CARDIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália